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Abstract
Polycomb (PcG) and trithorax (trxG) proteins play important roles in establishing lineage-specific genetic programs through
induction of chromatin modifications that lead to gene silencing or activation. Previously, we described an association
between the MLL/SET1 complexes and a highly restricted, gene-specific DNA-binding protein Ap2d that is required for
recruitment of the MLL/SET1 complex to target Hoxc8 specifically. Here, we reduced levels of Ap2d and Ash2l in the
neuroblastoma cell line, Neuro2A, and analyzed their gene expression profiles using whole-genome mouse cDNA
microarrays. This analysis yielded 42 genes that are potentially co-regulated by Ap2d and Ash2l, and we have identified
evolutionarily conserved Ap2-binding sites in 20 of them. To determine whether some of these were direct targets of the
Ap2d-Ash2l complex, we analyzed several promoters for the presence of Ap2d and Ash2l by chromatin immunoprecip-
itation (ChIP). Among the targets we screened, we identified Fgfr3 as a direct transcriptional target of the Ap2d-Ash2l
complex. Additionally, we found that Ap2d is necessary for the recruitment of Ash2l-containing complexes to this promoter
and that this recruitment leads to trimethylation of lysine 4 of histone H3 (H3K4me3). Thus, we have identified several
candidate targets of complexes containing Ap2d and Ash2l that can be used to further elucidate their roles during
development and showed that Fgfr3 is a novel direct target of these complexes.
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Introduction
PcG and trxG proteins act antagonistically to maintain
heritable patterns of gene expression, with the former marking
genes for repression and the latter for activation. PcG
complexes are associated with trimethylation of histone H3 at
lysine 27 (H3K27me3) whereas trxG complexes are linked to
H3K4me3 [1,2]. This relationship embodies the characteristic
of cellular memory to establish the identity in each cell type
during development. Previously, these marks were considered to
be static; recent evidence, however, has shown that these marks
are involved in dynamic gene regulation through active
recruitment of PcG and trxG complexes during cellular
differentiation [2,3]. Studies using embryonic stem (ES) cells
and neural and muscle progenitors reveal that these marks vary
depending on the cell type and that the majority of these marks
is present at the promoters of key developmental genes [3,4].
Furthermore, experiments that are based on chromatin immu-
noprecipitation coupled to DNA microarray analysis (ChIP-
chip) and the more recent ChIP-seq, in which enriched DNA is
directly sequenced, reveal an association between the intensity
of the H3K4me3 epigenetic mark at the promoter and active
transcription [3]. Conversely, the presence of the H3K27me3
mark is associated with gene repression [3]. These data suggest
that PcG and trxG proteins play a role in establishing lineage-
specific genetic programs through induction of chromatin
modifications.
The trxG protein group includes members of the MLL/SET1
family of histone lysine methyltransferases (HKMTs) and their
associated proteins. The MLL/SET1 family consists of six
members, Mixed Lineage Leukemia 1 (MLL1), MLL2 (ALR),
MLL3 (HALR), MLL4, SET1A and SET1B, which share a
catalytic SET domain that has been shown to have H3K4
methyltransferase activity [5,6,7,8]. MLL/SET1 proteins exist in
multimeric complexes that contain three highly conserved
subunits: Ash2l, RbBP5 and WDR5 [9]. Recently, it had been
reported that these subunits are important for regulating the
enzymatic activity of the SET domain-containing factor. Ash2l, in
particular, was shown to be critical for H3K4me3 as downregu-
lation of Ash2l leads to a genome-wide decrease in this epigenetic
mark [10].
We recently reported that the gene-specific transcription factor
Activating protein 2d (Ap2d) is important for the recruitment of
MLL2 to the Hoxc8 locus during embryogenesis and that this
recruitment leads to H3K4me3 and subsequent gene activation
[11]. Ap2d is a member of the Ap2 family of sequence-specific
DNA-binding proteins, which consists of Ap2a,- b,- c,- d and -e.
Ap2 proteins bind a GC-rich consensus sequence that is found on
a variety of cellular and viral enhancers. Ap2d is considered the
most divergent family member, as it has a unique transactivation
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Additionally, Ap2d’s gene, Tcfap2d, has a highly restricted
expression pattern and is found in the developing myocardium,
central nervous system and retina [12].
To search systematically for Ap2d- and Ash2l-regulated targets,
we assessed the transcriptome using cDNA microarrays to identify
genes whose expression was significantly decreased when either
protein was diminished and then filtered those results using the
criterion of an evolutionarily conserved Ap2-binding site in the
promoter. To identify true targets of Ap2d and Ash2l-containing
complexes among several candidates, we tested for the presence of
Ap2d and Ash2l at their promoters. Among the genes we tested,
we identified Fgfr3 as a direct target of Ap2d and Ash2l given that
both proteins were present at the Fgfr3 promoter and that
downregulation of either Ap2d or Ash2l resulted in a decrease of
Fgfr3 expression. Thus, we provide evidence suggesting that Ap2d
plays an important role in altering the epigenetic landscape of a set
of developmentally regulated targets through recruitment of
Ash2l-containing HKMT complexes.
Results
Identification of Ap2d and Ash2l Target Genes by cDNA
Microarray Analysis
To identify targets of Ap2d and Ash2l, we performed whole
genome analysis of cDNA expression levels obtained from
Neuro2a cells treated with either Tcfap2d- or Ash2l-specific RNAi
or a scrambled control. As shown in Fig. 1, treatment with either
Tcfap2d-o rAsh2l-specific RNAi resulted in a significant decrease of
their respective transcripts only. Previously, we had shown that
treatment with Ash2l-specific RNAi resulted in a decrease in Ash2l
protein only [11].
To systematically identify genes regulated by both Ap2d and
Ash2l at the genome-wide scale, we obtained cDNAs from RNAi-
treated Neuro2a cells and performed microarray analysis using the
GeneChipH Mouse Genome 430 2.0 Array. Triplicate microarray
experiments were performed comparing signals obtained from
cells treated with either Tcfap2d-o rAsh2l-specific RNAi to those of
cells treated with a scrambled control. Signal values were
calculated using the MAS5 and PLIER statistical algorithms.
Genes that had a significance level of p,0.05 and a fold change
greater than 1.1 were selected for analysis. Using signal values
obtained from the MAS5 probe summarization algorithm, we
identified 917 and 806 genes that were differentially expressed
when Ap2d or Ash2l, respectively, was downregulated. Compar-
ison of these two groups yielded 76 genes whose expression was
significantly altered when Tcfap2d and Ash2l were knocked down
individually (Fig. 2A). Given that Ap2d and Ash2l form a complex
that is involved in H3K4me3, we assumed that a reduction in
either Ap2d or Ash2l would lead to decreased expression of their
direct targets. Hence, to identify candidate targets of the Ap2d-
Ash2l complex, we focused solely on genes that were downreg-
ulated when they were reduced. Of the 76 genes whose expressed
was significantly changed when Ap2d and Ash2l were decreased,
33 genes with known function were downregulated. To determine
whether we could identify additional targets that had not been
previously identified by MAS5, we applied an alternative method
using the PLIER probe summarization algorithm to obtain signal
values. Through this method, we identified 9 additional genes that
were downregulated when Ap2d and Ash2l levels were decreased.
Altogether, 42 genes were identified as candidate targets of the
Ap2d-Ash2l complex (Fig. 2B).
Functional annotation was performed based on gene ontology
(GO) for the 42 genes that were downregulated in RNAi-treated
cells (Table 1). A majority of the genes encodes for proteins
that are involved in particular developmental functions, such as
transcriptional regulation and signal transduction (Fig. 2C).
Indeed, a significant enrichment of transcriptional regulators was
identified in our analysis as only a small percentage (,4%) of
genes encode for this class of genes in the mouse genome [14].
Additionally, these gene functions are consistent with the role of
both Ap2d and Ash2l in development. We therefore concluded
that these genes were probable targets of the Ap2d-Ash2l
complex. Altogether, these candidate targets may shed some
insight into the role of the Ap2d-Ash2l complex during
development.
Figure 1. Tcfap2d and Ash2l are downregulated in Neuro2a cells treated with either Ap2d or Ash2l RNAi. Total RNA was extracted 72
hours post-transfection from Neuro2a cells treated with Tcfap2d-o rAsh2l-specific siRNA or scrambled control. Gapdh, Tcfap2d and Ash2l transcript
levels were quantified by real-time PCR. Normalized values were calculated as percentages of transcript levels detected in cells treated with the
scrambled control. Significant differences are as indicated with * (p#.001).
doi:10.1371/journal.pone.0008535.g001
Fgfr3 Is a Target of Ap2d
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in the Promoter Region of Putative Targets
To identify direct targets of the Ap2d-Ash2l complex, we
searched the promoters of the 42 candidate genes for evolution-
arily conserved Ap2-binding sites using rVista 2.0 [15]. We
analyzed genomic sequences up to 5 kilobases (kb) upstream and
2 kb downstream of the transcriptional start site (TSS). Of the 42
candidate targets tested, we found highly conserved Ap2-binding
sites in 21 of 42 genes we assessed (Table 1). Given that a number
of the candidate genes had Ap2-binding sites within 5 kb of the
TSS, we concluded that these genes with Ap2-binding sites might
be direct targets of the Ap2d-Ash2l complex.
Knockdown of Tcfap2d and Ash2l Leads to Decreased
Expression of Candidate Ap2d and Ash2l Targets
To determine whether candidate targets with evolutionarily
conserved Ap2-binding sites were indeed regulated by Ap2d and
Ash2l, we investigated the expression level of these targets upon
downregulation of Ap2d or Ash2l. We selected a number of genes
that had roles in transcriptional regulation, development and
signal transduction and tested the expression level of these genes
using quantitative RT-PCR. Steady-state transcript levels for
Plexin A3 (Plxna3), Fibroblast growth factor receptor 3 (Fgfr3) and
Dickkopf homolog 3 (Dkk3) were significantly downregulated in
Neuro2a cells after treatment with either Tcfap2d-o rAsh2l-specific
RNAi (Fig. 3). Plxna3, Fgfr3 and Dkk3 encode proteins that play
important roles in neuronal development [16,17,18]. Ap2d,i n
turn, has been implicated in neuronal development due to its
highly restricted expression pattern in this tissue during embryo-
genesis [12]. Furthermore, MLL complexes have been implicated
in neuronal differentiation, as MLL recruitment leads to increased
H3K4me3 and activation of neuronal-specific genes [19]. Given
that the candidate genes have overlapping roles in neuronal
development with Ap2d and Ash2l-containing complexes, we
predicted that these candidate genes were likely to be direct targets
of Ap2d and Ash2l.
Ap2d Recruits Ash2l to the Fgfr3 Locus and Promotes
H3K4me3
To identify direct targets of Ap2d and Ash2l, we determined
whether these proteins were present on the Fgfr3, Plxna3 and Dkk3
promoters. We hypothesized that Ap2d and Ash2l would bind the
promoters of these genes through highly conserved Ap2-binding
sites that were previously identified in silico. To test this hypothesis,
we performed chromatin immunoprecipitation (ChIP) using
antibodies against V5/Ap2d and Ash2l and analyzed the bound
DNA by quantitative PCR. We found that Ap2d and Ash2l were
present only at the Fgfr3 promoter. Additionally, these proteins co-
localized at various regions of the promoter that were highly
enriched in evolutionarily conserved Ap2-binding sites (Fig. 4A).
These regions include the sites ,1.2 kb (21.2 kb) upstream and
,200 bp (TSS) and ,1.4 kb (+1.4 kb) downstream of the TSS.
To determine whether Ap2d recruits Ash2l-containing histone
methyltransferases to the Fgfr3 promoter, we performed ChIP
analysis with anti-Ash2l antibodies and Neuro2a cells treated with
Tcfap2d-specific siRNA. Downregulation of Ap2d significantly
decreased the association of Ash2l with the 21.2 kb, TSS and
+1.6 kb sites (Fig. 4B). Having demonstrated an Ap2d-dependent
recruitment of Ash2l, we next determined whether this recruit-
ment altered H3K4 trimethylation at the Fgfr3 locus, as this
epigenetic status marks transcriptional initiation [20,21]. We
performed ChIP experiments using anti-trimethylated H3K4
antibodies with chromatin fragments obtained from Neuro2a cells
Figure 2. Ap2d and Ash2l regulate a variety of genes involved
in development. (A) Downregulation of Tcfap2d and Ash2l in cells
leads to the differential expression of 917 and 806 genes, respectively.
Comparison of these groups yields 76 genes whose expressions are
changed when both Tcfap2d and Ash2l levels are reduced. (B) Among
the 713 and 409 genes that are downregulated when Tcfap2d or Ash2l
are decreased, respectively, 42 genes are decreased when both genes
are reduced. (C) Functional annotation based on gene ontology (GO)
reveal that the majority of the 42 genes encode for a variety of
developmental proteins involved in transcriptional regulation and
signal transduction. Microarray analysis was performed with cDNAs
obtained from Neuro2a cells treated with either Tcfap2d-o rAsh2l-
specific RNAi or a scrambled control. Signal values were calculated
using the MAS5 and PLIER statistical algorithms. Genes with a
significance level of p,0.05 as compared to the scrambled control
were selected for analysis.
doi:10.1371/journal.pone.0008535.g002
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Gene Title Gene Symbol Accession Number Number of motifs
Transcription factors and regulators rVista*
expressed sequence AA407331 AA407331/Smad2 NM_010754.4 7
DAZ interacting protein 1-like Dzip1l NM_028258
EBNA1 binding protein 2 Ebna1 bp2 NM_026932 1
eukaryotic translation initiation factor 2C, 3 Eif2c3 NM_153402 1
Kruppel-like factor 5 Klf5 NM_009769 3
leucine rich repeat and fibronectin type III domain containing 1 Lrfn1 NM_030562 8
nuclear factor I/X Nfix NM_001081981 12
zinc finger homeobox 3 Zfhx3 NM_007496 17
zinc finger protein 655 Zfp655 NM_028298
zinc finger, MYM-type 6 Zmym6 NM_177462
Secreted factors
dickkopf homolog 3 Dkk3 NM_015814
Signal transduction
ATP-binding cassette, sub-family D (ALD), member 1 Abcd1 NM_007435 3
rho/rac guanine nucleotide exchange factor (GEF) 18 Arhgef18 NM_133962
DIX domain containing 1 Dixdc1 NM_178118 4
fibroblast growth factor receptor 3 Fgfr3 NM_008010 8
gamma-aminobutyric acid (GABA-A) receptor, pi Gabrp NM_146017
GTPase activating protein and VPS9 domains 1 Gapvd1 NM_025709 2
Differentiation/Development/Tissue specific expression
crystallin, zeta Cryz NM_009968
filamin, beta Flnb NM_134080
low density lipoprotein receptor-related protein 4 Lrp4 NM_172668 6
plexin A3 Plxna3 NM_008883 6
Nucleotide metabolism
arginine/serine-rich coiled-coil 2 Rsrc2 NM_001005525 2
Protein metabolism
argininosuccinate lyase Asl NM_133768
carbonic anhydrase 11 Car11 NM_009800
Esterase D/formylglutathione hydrolase Esd NM_016903
flavin containing monooxygenase 2 Fmo2 NM_018881
histocompatibility (minor) HA-1 Hmha1 NM_027521 2
Zinc finger, DHHC domain containing 13 Zdhhc13 NM_028031 1
Intracellular Transport
spire homolog 1 (Drosophila) Spire1 NM_194355
vacuolar protein sorting 13B (yeast) Vps13b AK122302
Ubiquitination
BRCA1/BRCA2-containing complex, subunit 3 Brcc3 NM_145956
ubiquitin-activating enzyme E1, Chr Y 1 Ube1y1 NM_011667
Proteolysis
AE binding protein 1 Aebp1 NM_009636
methionine aminopeptidase-like 1 Metapl1 NM_025633 1
protease, serine, 36 Prss36 NM_001081374
Actin Cytoskeleton Organization
coronin, actin binding protein, 2B Coro2b NM_175484
Transport
ATPase, class II, type 9A Atp9a NM_015731 8
Cell Cycle/Apoptosis
cell division cycle and apoptosis regulator 1 Ccar1 NM_026201
Fgfr3 Is a Target of Ap2d
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We found significantly reduced levels of H3K4 trimethylation at
the Fgfr3 locus when Ap2d was downregulated (Fig. 4C). These
results indicate that Ap2d recruits Ash2l to the Fgfr3 promoter
resulting in H3K4me3 and increased gene activation. It should be
noted that downregulation of Ap2d did not alter Ash2l and Alr
protein levels similar to previous results [11].
Discussion
In this study, we identified a number of candidate targets of
Ap2d and Ash2l by comparing the gene expression profiles of
Neuro2a cells treated with Tcfap2d-o rAsh2l-specific RNAi.
Functional classification of probable Ap2d- and Ash2l-regulated
targets revealed an overrepresentation of genes involved in
transcriptional regulation, signal transduction and development.
We also identified a number of genes that were involved in the
Wnt/b-catenin pathway (Dixdc1, Dkk3, Lrp4, AA407331/Smad2)
and the small GTPase-mediated signaling pathway (Arhgef1,
Gapvd1) implying a probable role of Ap2d and Ash2l-containing
complexes in these developmental pathways. Moreover, a
significant portion of these candidate genes (21 out of 42)
contained evolutionarily conserved Ap2-binding sites. We dem-
onstrated that one of the three candidate genes we assessed, Fgfr3,
was indeed a direct target of Ap2d and Ash2l given that both
proteins co-localized at the promoter and that downregulation of
Ap2d or Ash2l resulted in decreased Fgfr3 expression. Given that
we had only assessed a limited window for Ap2-binding sites and
only those sites for Ap2d-Ash2l binding, it should be noted that the
genes for which we did not find any Ap2 binding sites might have
binding sites further up- and downstream of the regions that we
had assessed. As such, genes that were downregulated but for
which we failed to find an Ap2-binding site are not necessarily false
positives or indirectly regulated.
A growing body of evidence has shown that Fgfr1, -2 and -3
play important roles in the proliferation and differentiation of
neural stem cells (NSCs). Immunocytochemical studies with NSCs
derived from E15 rat striatum showed that expression of these
receptors is developmentally regulated and cell lineage-specific.
During the first day of culture, 50% and 70% of the NSCs or early
precursors expressed Fgfr1 and -2, respectively, while a restricted
population expressed Fgfr3 [22]. After 10 days in culture, the
number of cells expressing Fgfr1 and -2 was significantly decreased
to 15% of the total cell number whereas those expressing Fgfr3
comprised a significant portion of the population suggesting that
Fgfr3 is increased during the process of cellular differentiation [22].
Gene Title Gene Symbol Accession Number Number of motifs
dendrin Ddn AK158894 4
Nuclear mitotic apparatus protein 1 Numa1 NM_133947
Disease
carnitine deficiency-associated gene expressed in ventricle 3 Cdv3 NM_175565 4
Misc
follicular lymphoma variant translocation 1 Fvt1 NM_027534
*Number of evolutionarily conserved Ap2-binding sites within 5 kb upstream and 2 kb downstream of the transcriptional start site (TSS).
doi:10.1371/journal.pone.0008535.t001
Table 1. Cont.
Figure 3. Ap2d and Ash2l regulate Plxna3, Fgfr3 and Dkk3 expression in Neuro2a cells. Plxna3, Fgfr3 and Dkk3 are downregulated
when Ap2d and Ash2l are downregulated. Total RNA was extracted 72 hours post-transfection from Neuro2a cells treated with Tcfap2d-o r
Ash2l-specific siRNA or scrambled control. Gapdh, Zfhx3, Plxna3, Fgfr3, Dkk3 and Sp7 transcript levels were quantified by real-time PCR. Normalized
values were calculated as percentages of transcript levels detected in cells treated with the scrambled control. Significant differences are as indicated
with * (p#.05).
doi:10.1371/journal.pone.0008535.g003
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terminal differentiation while Fgfr1 and -2 may be important for
earlier events, such as cell specification. Additionally, these Fgfr-
positive cells were probed with various cell-lineage markers to
determine whether there was an enrichment of a specific Fgfr in a
particular cell lineage. Fgfr1 and -2 were detected in early
oligodendroglial precursors whereas Fgfr3 was detected in early
oligodendroglial precursors, oligodendrocytes and astrocytes [22].
These data suggest that Fgfr1–3 play specific roles in the
differentiation of NSCs into neurons, oligodendrocytes and
astroctyes. To demonstrate that Fgfr1, 2 and 3 have roles in
neuronal differentiation, NSCs were treated with basic FGF
(bFGF), which is a ligand for these receptors. As predicted,
treatment with exogenous bFGF resulted in increased proliferation
of NSCs and an increased number of oligodendrocytes after seven
days in culture [22]. Recently, mice were generated carrying
various combinations of Fgfr mutant alleles to establish the role of
Fgfr in vivo [23]. As predicted, mice with mutations in two or three
Fgfr genes demonstrated patterning defects and increased apoptosis
in the CNS, supporting the notion that Fgfr’s are important for cell
survival and identity [23]. Altogether, these data imply that Fgfr1,
-2 and -3 play important roles in the ability of NSCs to self-renew
and differentiate into distinct neuronal cell types. Moreover, their
expressions in the developing CNS overlap with that of Tcfap2d
confirming the role of Ap2d in Ffgr3 regulation during develop-
ment [24]. Indeed, these roles are consistent with those of trxG
proteins whose functions have been linked to cell differentiation
and memory.
Although we identified several Ap2d- and Ash2l-regulated
genes, a vast majority of differentially expressed genes did not
overlap when the gene expression profiles were compared between
cells treated with Tcfap2d-specific RNAi and those treated with
Ash2l-specific RNAi. Given that Ash2l and its associated proteins
are expressed ubiquitously, we hypothesized that Ash2l achieved
its specificity through interactions with developmentally regulated
transcription factors, such as Ap2d. This would imply that Ash2l
would have functions independent of those attributed to Ap2d.
Indeed, we found that only 76 out of 806 differentially expressed
genes in Ash2l RNAi-treated cells overlapped with those in Ap2d
RNAi-treated cells. Similarly, Ap2d may also interact with other
co-activators, such as histone acetyltransferases and lysine
demethylases, to activate its downstream targets. Previously, it
had been reported that Ap2 proteins interacted with Cited2 and
CBP to activate their targets indicating that Ap2d may also
Figure 4. Ap2d recruits Ash2l-containing HMT complexes to the Fgfr3 locus in Neuro2a cells. (A)( Top) Ap2d and Ash2l bind specific
regions of the Fgfr3 promoter that are highly enriched in evolutionarily conserved Ap2-binding sites. The sites are located at the transcriptional start
site (TSS) and regions ,1.2 kb (21.2 kb) upstream and ,1.4 kb (+1.4 kb) downstream of the TSS. (Bottom) Western blot analysis show expression of
Ap2d/V5 in Neuro2a cells transfected with either an empty vector or an Ap2d/V5 expression construct. (B) Ap2d downregulation results in decreased
localization of Ash2l at the promoter concomitant with reduced HK4me3 (C). (D) Real-time PCR analysis shows a specific downregulation of Tcfap2d
transcripts in Neuro2a cells treated with Tcfap2d-specific siRNA only. Normalized values were calculated as percentages of transcript levels detected
in cells treated with the scrambled control. Significant differences are as indicated with * (p#.05) and ** (p#.005).
doi:10.1371/journal.pone.0008535.g004
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This hypothesis is further supported by the observation that
interactions with Cited2 and CBP occur in regions of the Ap2
protein that are nearly identical among Ap2 family members
including Ap2d. As such, Ap2d’s interaction with Ash2l may occur
independently or in addition to its interaction with Cited2 and
CBP. These interactions would, in turn, result in a repertoire of
genes that are regulated by Ap2d independently of Ash2l. Our
results are consistent with this hypothesis, as only 76 out of 917
differentially expressed genes in Ap2d RNAi-treated cells over-
lapped with those in Ash2l RNAi-treated cells.
It had been suggested that Ash2l and its associated proteins,
including the MLL/SET1 subunits, are global regulators of gene
expression given their expression patterns and developmental
functions. As such, deletion of Ash2l or any of its associated proteins
may result in either embryonic lethality or a pleiotropic defect that
could potentially mask a variety of distinct developmental
phenotypes. To circumvent this issue, one could potentially analyze
the role of Ash2l through analysis of its various regulators, such as
Ap2d. Our studies are, therefore, an initial step in elucidating the
function of Ash2l in vivo, providing a library of genes and pathways
that are potentially regulated by Ash2l when it interacts with Ap2d.
Additionally, our studies in Neuro2a cells using endogenous proteins
may reflect to a limited extent conditions similar to that of neural
progenitors in vivo. Given that Neuro2a cells have oncogenic
properties, these targets will need to be validated in vivo.
In conclusion, we have identified a library of genes that are
regulated by both Ap2d and Ash2l. A significant portion of these
candidate target genes contains evolutionarily conserved Ap2-
binding sites implying that several of them are direct targets of the
Ap2d and Ash2l-containing HMT complexes. Among the targets
we screened, we identified Fgfr3 as a novel target of both Ap2d and
Ash2l. Thus, we provide evidence that these candidate genes will be
useful in elucidating the developmental roles of Ap2d and Ash2l.
Materials and Methods
Cell Culture and Immunoblotting
Neuro2a cells (ATCC, Manassas, VA) were maintained in
Dulbecco’s Modified Eagle Medium (Invitrogen) supplemented
with 10% (v/v) fetal bovine serum and antibiotics (Invitrogen) at 37
uC with 5% CO2. Confluent cells were transfected with constructs
expressing Ap2d/V5 using Lipofectamine 2000 (Invitrogen) at a
DNA-to-transfection reagent ratio of 1:3. Cells were harvested in
PBS after 48 h and incubated in lysis buffer (50 mM Tris-HCl
pH 8.0, 1% Triton X-100, 150 mM NaCl, 10 mM EDTA)
supplemented with 1X Protease Inhibitors (Roche, Indianapolis,
IN). Lysates were resolved by 10% SDS-PAGE and electrotrans-
ferred onto nitrocellulose membranes. Immunoblots were probed
with anti-V5 (Invitrogen) and anti-Gapdh antibodies (Sigma
Aldrich, St. Louis, MO) that were detected by chemiluminescence
according to protocol (Amersham Biosciences, Piscataway, NJ).
RNA Analysis
For siRNA knockdown experiments, Neuro2a cells were
transfected with Tcfap2d-o rAsh2l-specific siRNA or a scrambled
control using Dharmafect 1 (Dharmacon, Lafayette, CO), and total
RNA isolated 72 h post transfection.TotalRNAwas extracted using
Trizol reagent according to the manufacturer’s protocol (Invitrogen)
and reverse transcribed using Superscript
TM III reverse transcriptase
and oligo-dT primers (Invitrogen). Transcript levels were deter-
mined by real-time PCR using Gapdh as an internal control.
Microarray Analysis
Total RNA was extracted from Neuro2a cells transfected with
either Tcfap2d- or Ash2l-specific siRNA using the RNeasy Kit
(Qiagen, Valencia, CA). Total RNA was reverse transcribed using a
T7-oligo d(T) primer (Affymetrix, Santa Clara, CA), and cDNA was
used as template for in vitro transcription using biotin-modified
ribonucleotides. Biotinylated cRNA targets were fragmented and
hybridized to Affymetrix GeneChip Mouse Genome 430 2.0 Arrays.
Arrays were subsequently washed, stained and scanned using an
AffymetrixGeneChipH-related software. ArrayAssist (Stratagene) was
used to determine statistical significance among probe sets that were
differentially expressed between gene-specific siRNA- and NTC-
treated samples. Probe sets that were changed at least 1.1-fold with a
p-value#0.05 were used for further studies. Triplicate arrays were
used for each sample to obtain statistical significance.
Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed according to manufacturer’s
protocol (Millipore Inc., Billerica, MA) [13]. Briefly, Neuro2a
cells were transfected with Ap2d/V5 or treated with RNAi for
72 h. Confluent cells were cross-linked in a solution containing 1%
formaldehyde for 10 min at room temperature, and the reaction
was terminated by the addition of glycine to a final concentration
of 0.1 M. Cells were washed twice in ice-cold PBS with protease
inhibitors (1 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml pepstatin
A) and harvested. Cells were lysed in SDS Lysis Buffer (Millipore)
containing protease inhibitors for 10 min on ice. Lysates were
sonicated to shear DNA into approximately 1-kb fragments. DNA-
containing fractions were diluted 10-fold with a ChIP dilution
buffer (Millipore) containing protease inhibitors. An equivalent
amount of chromatin was incubated with anti-V5, -Ash2l, -
trimethylated H3K4 (Millipore) or IgG antibodies overnight at
4uC. Immunoprecipitated material was collected with protein A
agarose beads (Millipore) and washed sequentially with a low salt-
immune complex wash buffer (Millipore), a high salt-immune
complex wash buffer (Millipore), LiCl Immune Complex Wash
Buffer (Millipore) and 1X TE (10 mM Tris-HCl, pH 8.0, 1 mM
EDTA) for 5 min on a rotator at 4uC. Complexes were eluted
from the Protein A-bound antibodies by addition of elution buffer
(1% SDS, 0.1 M NaHCO3). Cross-linking reactions were reversed
by heating at 65uC for 4 h. The DNA was recovered from
immunoprecipitated material by proteinase K treatment at 55uC
for 1 h followed by phenol/chloroform (1:1) extraction, ethanol
precipitation, and resuspension into 50 ml of nuclease-free water.
Recovered DNA was analyzed by end-point and real-time PCR
using the following loci-specific primers: Fgfr3 F1 59-CCCTGG-
GGTGGCATCCTG-39, Fgfr3 R1 59-AAGGACCCCTCCCTG-
CAGACT-39, Fgfr3 F2 59-GACAGAGGAGACCCTGGAA-
AAGC-39, Fgfr3 R2 59- ATATCTCACCCCCTGACTGCT-
TCTG-39, Fgfr3 F3 59-GAGATGAGGGGCGGTTGTCC-39
and Fgfr3 R3 59-GTGGCTCCCTTTCGCATCCTT-39.
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